Influenza is a leading cause of death and morbidity in the U.S. It results in up to 56,000 deaths, 710,000 hospitalizations and $10+ billion in medical costs each year. The 2009 H1N1 pandemic infected 35% of the population and cost $800+ billion – in just one year. Nearly a decade later, today’s flu vaccines are still only 50-65% effective and current antivirals have high resistance rates and low efficacy levels.
Virvio has created an anti-flu minibinder to address influenza. Our candidate is a computationally designed protein with demonstrated pre and post-exposure efficacy against the disease. Our anti-flu minibinder neutralizes multiple variants like H1N1 and H5N1 better than today’s standard of care while keeping immunogenicity low enough to allow chronic treatments. We are now developing a countermeasure for global distribution in a self-administered, disposable inhaler that is shelf-stable.